<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Alfonso, Fernando</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">RIBS IV: EES Superior to Paclitaxel-Eluting Balloon for Treating DES Restenosis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment of drug-eluting stent in-stent restenosis (DES-ISR) is challenging. Results from the Restenosis Intra-Stent of Drug-Eluting Stents: Paclitaxel-Eluting Balloon vs Everolimus-Eluting Stent trial [RIBS IV; NCT01239940] indicate that DES provide superior late angiographic clinical outcomes compared with drug-eluting balloons.</style></abstract><number><style face="normal" font="default" size="100%">30</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>